Clinical Trials Sponsored by Beijing Bio-Institute Biological Products Co., Ltd., formerly Beijing TiantanBio

Total 35 results

PATH
Beijing Bio-Institute Biological Products Co., Ltd., formerly Beijing TiantanBio

Completed

Immunogenicity and Safety of Liquid Bivalent Oral Poliomyelitis Vaccine

Poliomyelitis

Kenya
National Vaccine and Serum Institute, China
Beijing Institute of Biological Products Co Ltd.; Lanzhou Institute of Biological...

Active, not recruiting

Phase I Clinical Trial of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above

COVID-19 Pneumonia

China
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd.

Active, not recruiting

A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTaP)

Whooping Cough | Tetanus | Diphtheria

China
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd.

Active, not recruiting

A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated (COVID-19)

Covid19

China
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd.

Completed

Immuno-bridging Study of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 3-17 vs Aged 18 Years Old and Above (COVID-19)

COVID-19 | COVID-19 Pneumonia

United Arab Emirates
National Vaccine and Serum Institute, China
China National Biotec Group Company Limited; Lanzhou Institute of Biological... and other collaborators

Recruiting

Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above

Coronavirus Infections | COVID-19 Pneumonia

United Arab Emirates
China National Biotec Group Company Limited
The University of Hong Kong; Beijing Institute of Biological Products Co Ltd.; Wuhan Institute of Biological Products Co., Ltd

Active, not recruiting

Sequential Immunization of Two Doses of Inactivated COVID-19 Vaccine (Omicron) in Vaccinated Population Aged 18 Years and Above (COVID-19)

COVID-19

Hong Kong
National Vaccine and Serum Institute, China
China National Biotec Group Company Limited; Beijing Institute of Biological... and other collaborators

Recruiting

Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical Trial

Coronavirus Infections | COVID-19

United Arab Emirates
National Vaccine and Serum Institute, China
China National Biotec Group Company Limited; Beijing Institute of Biological... and other collaborators

Recruiting

A Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell)

COVID-19

United Arab Emirates
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd.; Shulan (Hangzhou) Hospital

Active, not recruiting

A Study to Evaluate the Safety and Immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in Population 18 Years Old of Age and Above (COVID-19)

COVID-19

China
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd.; Wuhan Institute of Biological... and other collaborators

Completed

A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above (COVID-19)

COVID-19

Jordan, Bahrain, Egypt, United Arab Emirates
China National Biotec Group Company Limited
Peking University; Beijing Institute of Biological Products Co Ltd.; Beijing...

Completed

Immunogenicity and Safety of Sabin-IPV Replacement Vaccination

Vaccination

China
National Vaccine and Serum Institute, China
Zhengzhou University; Lanzhou Institute of Biological Products Co., Ltd; Beijing...

Active, not recruiting

A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19

COVID-19

China
National Vaccine and Serum Institute, China
Zhengzhou University; Lanzhou Institute of Biological Products Co., Ltd; Beijing...

Recruiting

Clinical Trial to Evaluate the Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenula Polymorpha)

Norwalk Gastroenteritis | Norovirus Infections

China
National Vaccine and Serum Institute, China
Zhengzhou University; Lanzhou Institute of Biological Products Co., Ltd; Beijing...

Completed

A Clinical Trial to Evaluate the Safety and Immunogenicity of Norovirus Bivalent Vaccine

Norwalk Gastroenteritis | Norovirus Infections

China
Laboratorio Elea Phoenix S.A.
China National Biotec Group Company Limited; Beijing Institute of Biological... and other collaborators

Completed

Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)

COVID-19 Virus Infection

Argentina
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd.; Sichuan Center for Disease... and other collaborators

Completed

Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4

Covid19 | Pneumonia, Pneumococcal | Influenza, Human

China
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd.; Guizhou Center for Disease... and other collaborators

Recruiting

Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies Vaccine

COVID-19 | Rabies

China
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd.; Wuhan Institute of Biological... and other collaborators

Unknown

Clinic Trial to Evaluate the Safety and Immunogenicity of Combined Immunization of sIPV and DTaP

Vaccination

China
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd.; Zhejiang Provincial Center...

Not yet recruiting

Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in Elderly People With Chronic Bronchitis and COPD

COVID-19 | COPD | Chronic Bronchitis

China
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd.; Jiangsu Province Center for...

Active, not recruiting

A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella Vaccine

Varicella

China
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd.; Hunan Provincial Center for...

Active, not recruiting

Study on Sequential Immunization of Omicron Inactivated COVID-19 Vaccine and Prototype Inactivated COVID-19 Vaccine in Population Aged 18 Years Old and Above (COVID-19)

COVID-19

China
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd.; Zhejiang Provincial Center...

Not yet recruiting

Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in People With HIV Infected

HIV Infections | COVID-19

China
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd.; Zhejiang Provincial Center...

Recruiting

Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Elderly People With Chronic Bronchitis and COPD

COVID-19 | COPD | Chronic Bronchitis

China
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd.; Zhejiang Provincial Center...

Recruiting

Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People With HIV Infected

HIV Infections | COVID-19

China
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd.; Jiangsu Province Center for...

Active, not recruiting

A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of Age

Varicella

China
National Vaccine and Serum Institute, China
Guangxi Center for Disease Control and Prevention; Simoon Record Pharma Information... and other collaborators

Completed

Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)

HPV Infection | HPV-Related Cervical Carcinoma

China
National Vaccine and Serum Institute, China
Guangxi Center for Disease Control and Prevention; Simoon Record Pharma Information... and other collaborators

Completed

A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years

HPV Infection | HPV-Related Cervical Carcinoma

China
China National Biotec Group Company Limited
Xiangya Hospital of Central South University; Beijing Institute of Biological... and other collaborators

Recruiting

Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis Population

COVID-19 | Hemolysis

China
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd.; Hubei Provincial Center for... and other collaborators

Unknown

Evaluation of Safety and Immunogenicity of Combined Immunization of sIPV, DTaP and HepA

Vaccination

China
China National Biotec Group Company Limited
Peking University; Beijing Institute of Biological Products Co Ltd.; Sichuan... and other collaborators

Completed

Evaluation of the Safety and Immunogenicity of Simultaneously Administration of sIPV and DTaP

Vaccination

China
China National Biotec Group Company Limited
Peking University; Beijing Institute of Biological Products Co Ltd.; Sichuan... and other collaborators

Unknown

Evaluation of Immunogenicity and Safety of Combined Immunization of sIPV, DTaP and MMR

Vaccine

China
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd.; Hunan Provincial Center for... and other collaborators

Completed

Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes

COVID-19 Pneumonia

China
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd.; Hunan Provincial Center for... and other collaborators

Not yet recruiting

Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes

COVID-19 Pneumonia

China
National Vaccine and Serum Institute, China
Sichuan Center for Disease Control and Prevention; Hunan Provincial Center... and other collaborators

Recruiting

A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years

HPV-Related Carcinoma | HPV InfectioN

China

Clinical Trials Sponsored by Beijing Bio-Institute Biological Products Co., Ltd., formerly Beijing TiantanBio

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations